Search

Displaying results 5851 - 5860 of 10000 in total
  1. Drug

    Rhizopus arrhizus var. arrhizus

    go.drugbank.com/drugs/DB10441
    Approved

    Rhizopus arrhizus var. arrhizus is a fungus which can provoke allergic reactions. Rhizopus arrhizus var. arrhizus extract is used in allergenic testing.

  2. Drug

    Puccinia striiformis var. striiformis

    go.drugbank.com/drugs/DB10937
    Approved

    Puccinia striiformis var. striiformis is a fungus which can provoke allergic reactions. Puccinia striiformis var. striiformis extract is used in allergenic testing.

  3. Drug

    BHV-1310

    go.drugbank.com/drugs/DB22674
    Experimental

    BHV-1310 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.

  4. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants

  5. Drug

    Rabies virus inactivated antigen, B

    go.drugbank.com/drugs/DB10062
    ApprovedInvestigational

    Inactivated rabies virus antigen B is a component of rabies vaccines used for pre- and post-exposure prophylaxis against rabies.[L12795]

  6. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    Dichloroacetic acid, often abbreviated DCA, is an acid analogue of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms. … DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market

  7. Drug

    Cianidanol

    go.drugbank.com/drugs/DB14086
    ApprovedInvestigationalWithdrawn

    An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.

  8. Drug

    Tavaborole

    go.drugbank.com/drugs/DB09041
    Approved

    Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes … Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).

  9. Drug

    Apronalide

    go.drugbank.com/drugs/DB13221
    Approved

    Apronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura [A174814].

  10. Drug

    NKG2D-ACE2 CAR-NK Cell

    go.drugbank.com/drugs/DB15727
    Investigational

    The ACE2 is a receptor for SARS-Cov-2, binding to the S-protein of the viral envelope and competitively inhibiting SARS-Cov-2 infection of type II alveolar epithelial cells. … These cells are prepared as universal off-the-shelf CAR-NK cells from cord blood with NKG2D-ACE2 proteins engineered as part of the CARs; the cell secretes IL-15 and GM-CSF.